The Latest Cardiac and Vascular News
JACKSONVILLE, Fla. and IRVINE, Calif., June 4, 2020 /PRNewswire/ — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today expanded a collaborative partnering effort for its lead product candidate tecarfarin. Tecarfarin is a Phase III-ready, vitamin K antagonist, taken once a day […]
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin […]
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Lee’s Pharmaceutical Holdings Limited and its subsidiaries (collectively “Lee’s Pharmaceutical”) has completed its Phase […]
JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs to treat forms of cardiovascular disease, today announced the appointment of Lee Golden, M.D. as Chief Medical Officer. In his role as […]
JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET […]
